Vertex to buy Crinetics for $10 billion, expanding into endocrinology

Vertex Pharmaceuticals agreed to buy Crinetics Pharmaceuticals for $85 a share in cash, a deal valuing the San Diego drugmaker at about $10 billion and pushing Vertex deeper into endocrinology. The acquisition would give Vertex a fifth therapeutic vertical and a sharper foothold in rare hormonal diseases, where large drugmakers are increasingly paying up for late-stage assets that can diversify revenue faster than internal research alone.

Crinetics said the offer values its equity at about $10.0 billion, or roughly $8.8 billion net of estimated cash acquired. The price represented a 102% premium to Crinetics’ Monday close, and the market reaction reflected both the size of the bid and the appeal of the pipeline. Crinetics shares jumped sharply in extended trading, while Vertex fell about 2%, a split that underscored investor enthusiasm for the strategy even as the premium looked rich.

For Vertex, the deal fits a clear pattern of trying to reduce reliance on cystic fibrosis, which remains its core business. Vertex reported $12.0 billion in full-year 2025 revenue, up 9% from 2024, and said non-cystic fibrosis products were expected to contribute $500 million or more in 2026 revenue. It also had about $12.0 billion in cash, cash equivalents and marketable securities as of June 30, 2025, giving it the balance sheet to fund another all-cash acquisition after its roughly $5.0 billion purchase of Alpine Immune Sciences in May 2024.

Crinetics brings assets that are already moving through or beyond the clinic. PALSONIFY, the company’s paltusotine brand, won European Commission approval on April 27, 2026, for adult acromegaly, and Crinetics says the drug is approved in the United States for adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ other major program, atumelnant, is a once-daily oral ACTH receptor antagonist in Phase 3 development for congenital adrenal hyperplasia, a disorder the company says affects about 17,000 addressable adult and pediatric patients in the United States.

The companies said the combined portfolio could produce more than $5 billion in peak annual sales, a figure that helps explain why endocrinology and rare disease have become so attractive to big biotech buyers. Scotiabank analyst Louise Chen said the transaction helps diversify Vertex away from its heavy concentration in cystic fibrosis, and the logic is plain: with patents expiring across the industry and investors rewarding predictable growth, the highest-priced future markets are increasingly small, specialized, and already late in development.